Danaher Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Danaher yıllık ortalama 9.3% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 11.7% annual. Gelirler growing yılda ortalama 5.1% oranında artmaktadır. Danaher'in özkaynak karlılığı 7.7% ve net marjı 16.6%'dir.

Anahtar bilgiler

9.3%

Kazanç büyüme oranı

8.6%

EPS büyüme oranı

Life Sciences Sektör Büyümesi21.5%
Gelir büyüme oranı5.1%
Özkaynak getirisi7.7%
Net Marj16.6%
Son Kazanç Güncellemesi27 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Understanding Danaher's Cautiousness

Oct 25

Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Sep 28
Is There Now An Opportunity In Danaher Corporation (NYSE:DHR)?

Danaher Q3 Preview: Market Share Gains In Molecular Testing

Sep 25

Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Sep 12
Is Danaher Corporation (NYSE:DHR) Trading At A 32% Discount?

Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly

Aug 28
Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly

Danaher: Lofty Price, Bright Future

Aug 22

Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

Aug 13
Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings

Danaher: Valuation Now Too High Even Compared To Own High Standards

Jul 16

What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Jun 23
What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?

Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum

Jun 20

Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Jun 05
Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?

Is Danaher (NYSE:DHR) A Risky Investment?

May 21
Is Danaher (NYSE:DHR) A Risky Investment?

It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

May 01
It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year

Value Vs. Growth? Danaher Says Why Not Both?

Apr 25

Danaher: All In On Life Sciences, And Market Update

Mar 27

Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Mar 11
Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?

Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Feb 10
Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings

Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term

Jan 30

Is Danaher (NYSE:DHR) Using Too Much Debt?

Jan 12
Is Danaher (NYSE:DHR) Using Too Much Debt?

My Top 2024 Stock Pick: Danaher

Dec 27

Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles

Nov 26

RGA Investment Advisors - Danaher:  Purity In The Crown Jewel Of Bioprocessing

Nov 19

Why Danaher Is One Of My Favorite Long-Term Investments

Oct 26

Danaher: Short-Term Headwinds, But Long-Term Tailwinds

Oct 17

Should Danaher Investors Sell New Veralto Shares?

Oct 02

Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Sep 30
Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price

Danaher: A Lost Year

Aug 30

Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens

Aug 02

Danaher: A Compounding Icon At A Fair Price

Jul 25

These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Jul 13
These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Jun 28
Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)

Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump

Jun 22

At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Jun 15
At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?

Danaher: A Great Chance To Buy This Long-Term Compounder

May 23

With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Apr 26
With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case

Gelir ve Gider Dağılımı

Danaher nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NYSE:DHR Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
27 Sep 2423,7423,9347,4701,549
28 Jun 2423,5684,0567,3581,528
29 Mar 2423,7374,0697,2811,498
31 Dec 2323,8904,2007,2451,503
29 Sep 2321,0264,4086,0801,332
30 Jun 2323,0655,0196,4891,390
31 Mar 2324,9045,7576,7621,460
31 Dec 2226,6436,2227,0801,528
30 Sep 2231,2506,6408,5721,787
01 Jul 2230,8166,2068,4891,808
01 Apr 2230,2836,2068,3691,803
31 Dec 2124,8025,2836,7631,498
01 Oct 2128,0655,6367,8181,643
02 Jul 2126,7205,3617,5431,544
02 Apr 2124,7994,5957,2781,441
31 Dec 2022,2843,5106,8801,348
02 Oct 2020,3923,0836,3541,246
03 Jul 2018,8862,8535,9541,186
03 Apr 2018,0342,6145,6591,146
31 Dec 1917,9112,3645,5771,126
27 Sep 1915,5622,0934,709980
28 Jun 1916,0372,1454,880998
29 Mar 1916,5732,1665,1251,028
31 Dec 1817,0492,4065,3561,059
28 Sep 1819,6152,7616,2461,211
29 Jun 1819,2902,6696,1731,189
30 Mar 1818,8192,5536,0721,160
31 Dec 1715,5192,1725,012956
29 Sep 1717,8282,3605,7641,098
30 Jun 1717,4322,1915,6331,060
31 Mar 1717,1642,0515,5361,016
31 Dec 1616,8822,1535,481975
30 Sep 1616,6211,9275,362943
01 Jul 1616,0011,9055,218914
01 Apr 1613,6631,7754,549788
31 Dec 1514,4341,7474,635861
02 Oct 1515,3351,8754,769926
03 Jul 1516,5302,1774,8651,002
03 Apr 1519,1862,5215,3481,143
31 Dec 1412,8671,6393,953769
26 Sep 1419,1972,6835,3051,189
27 Jun 1419,1592,5995,3111,210
28 Mar 1419,3362,5835,4051,267
31 Dec 1318,2832,5915,0421,104

Kaliteli Kazançlar: DHR yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: DHR 'nin mevcut net kar marjları (16.6%) geçen yılın (21%) değerinden daha düşüktür.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: DHR şirketinin kazancı son 5 yılda yılda 9.3% oranında arttı.

Büyüme Hızlandırma: DHR 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: DHR geçtiğimiz yıl negatif kazanç büyümesine ( -11% ) sahipti ve bu da onu Life Sciences sektör ortalamasıyla ( -4.7% ) karşılaştırmayı zorlaştırıyordu.


Özkaynak Getirisi

Yüksek ROE: DHR 'nin Özsermaye Getirisi ( 7.7% ) düşük olarak değerlendiriliyor.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin